60 patients with schizophrenia type paranoid treated in the Central hospital of Psychology were randomly divided into 2 groups: group I (30 patients): intensive intervention; group II (30 patient): control. The results have shown that the ages which starts suffering the disease were about 20-35; after 4 months of research on progress of the schizophrenia type paranoid and after chomotherapy and training for family in the publicity, the correct awareness, attitude for disease and ability of the social reintegration in the intervented group were better than these in the control
Schizophrenia, Paranoid ; Drug therapy

As a solution about many problems of pharmacotherapy for Korean patients with major psychiatric disorders, Korean Medication Algorithm Project for Major Psychiatric Disorders (KMAP) was launched. Recently, a medication algorithm for schizophrenic patients was developed and distributed. This review article showed the designs, processes and methods for developing this algorithm. Also we compared the development of Korean algorithm for schizophrenics with other foreign representative algorithms or clinical practice guidelines. We hope that this review elicit the productive criticism about the rigour, the system of development and the objectivity of content. The limitations and problems of Korean algorithm are also discussed in this review.
Drug Therapy ; Hope ; Humans ; Schizophrenia

Animal models of schizophrenia are important for research aimed at developing improved pharmacotherapies. In particular, the cognitive deficits of schizophrenia remain largely refractory to current medications and there is a need for improved medications. We discuss the pathophysiology of schizophrenia and in particular the possible mechanisms underlying the cognitive deficits. We review the current animal models of schizophrenia and discuss the extent to which they meet the need for models reflecting the various domains of the symptomatology of schizophrenia, including positive symptoms, negative symptoms and cognitive symptoms.
Animals ; Drug Therapy ; Humans ; Models, Animal ; Schizophrenia ; drug therapy ; physiopathology

Up to the present date, the principle of antipsychotics treatment in patients with schizophrenia is antipsychotics monotherapy. The reasons for the drug monotherapy may be associated with the fact that typical antipsychotics were assumed to have similar mechanism of action and that combination use of more than two antipsychotics would offer no benefit over that of monotherapy with the agents. However, because the newer `atypical' antipsychotics have the notable features in their diverse pharmacologic action and lower adverse event profiles, many practitioners have an interest in using the combination therapy. Some patients with schizophrenia and schizoaffective disorder have no response to atypical antipsychotics and the studies increasingly reported that the antipsychotics combinations improve the symptom profiles of psychotic patients. Thus, the antipsychotic combination therapy is an additional option in treatment-resistant psychotic patients. These combination therapies are commonly used in clinical practice, but we are in lack of the evidence of the rationale and background of this practice. Since most studies for antipsychotics combination therapy are open trial or retrospective study, we need the further prospective clinical studies with double-blind, placebo-controlled design in order to definitively determine the effectiveness of such practice.
Antipsychotic Agents* ; Drug Therapy, Combination ; Humans ; Psychotic Disorders ; Schizophrenia

After publishing 2001 version of the Korean Medication Algorithm for Schizophrenia, the strategy of pharmacologic treatment for schizophrenia has been altered with the rapid advancement in the area of psychopharmacology. Currently, the feasibility of this algorithm has been evaluated. Guidelines require updating when significant new evidence appears. Recently, several guidelines of the treatment of schizophrenia including the APA practice guideline, the Expert Consensus Guideline Series and the Texas Medication Algorithm Project (TMAP) Antipsychotic Algorithm for Schizophrenia were revised. In this review, the authors briefly discussed the problems and limitations of the Korean Medication Algorithm for Schizophrenia and presented the direction of future revision on the model of above-mentioned guidelines.
Consensus ; Drug Therapy ; Methods* ; Practice Guidelines as Topic ; Psychopharmacology ; Schizophrenia* ; Texas

The rapid development of psychotropic drugs and great advancement in psychopharmacology during the past recent years has altered the strategy of pharmacotherapy for major psychiatric disorders, and in turn, an active development of various clinical practice guidelines or algorithm has taken place. However, there could be problems with applying the foreign guidelines directly to our clinical situation, due to the differences in racial characteristics, socioeconomic conditions, government policy, and clinical practices. In addition, the changes of circumstances outside of clinical situation in Korea may distort clinical practices and may go even against the trend of recent psychopharmacology. As a solution to such problems, Korean Medication Algorithm Project for Major Psychiatric Disorders (KMAP) was launched with the support from the Korean Society of Psychopharmacology and Korean Academy of Schizophrenia. However, since clinical practice guidelines and algorithms contain not only the advantages, but also disadvantages and risks, sufficient consideration must precede the development of algorithms. Hence, this review provides a discussion on the definition of clinical guideline and its limitation, its advantages and disadvantages, and the need for the development of clinical guideline in psychiatric field. Also, developing source, dissemination and implementation of clinical practice guidelines were also discussed. We hope that this review can make the purpose of KMAP clear and elicit the productive criticism on Korean algorithm.
Drug Therapy ; Hope ; Korea ; Psychopharmacology ; Psychotropic Drugs ; Schizophrenia

The case of a 19-year-old man with coexistent narcolepsy and psychotic symptoms was presented. The psychotic symptoms were induced and / or exacerbated by methylphenidate. In addition, they were considered as symptoms of schizophrenia which had been developed regardless of the use of methylphenidate. The case illustrates the difficulties in diagnosing and treating, in particular, pharmacotherapy.
Drug Therapy ; Humans ; Methylphenidate ; Narcolepsy* ; Schizophrenia ; Young Adult

The negative symptoms and cognitive symptoms of schizophrenia patients are still clinical problems to be solved. Schizophrenia patients are abnormal in oxidative stress, immune regulation, and anti-histone deacetylase (HDAC), while sulforaphane plays a role in anti-oxidative stress, anti-inflammation, and anti-HDAC. Therefore, the sulforaphane could improve the negative symptoms and cognitive deficits of schizophrenia.
Cognition ; Humans ; Isothiocyanates ; therapeutic use ; Schizophrenia ; drug therapy

Humans ; Histamine ; Receptors, Histamine H2 ; Schizophrenia/drug therapy*

Electroconvulsive therapy (ECT) is a safe and effective treatment not only for various mental disorders including depression, mania, and schizophrenia, but also for inadequacy and resistance to pharmacotherapy and the psychiatric emergences. The historical ups and downs of ECT treatment since its first introduction in 1938 were ended by the validation impacts of evidence-based medicine in the 1980s and by other clinical issues. Clinical research for the optimization of ECT to maximize therapeutic effects and to minimize adverse effects is ongoing to establish standardized procedures and educational programs through the ECT center. In addition, guidelines for ECT practices are also being developed for the clinical excellence of ECT practices in accordance with the recommendations of international organizations such as World Psychiatric Association and American Psychiatric Association. This article was prepared by reviews of the literature, direct observations of ECT practices abroad, and interviews with ECT experts around the world in order to enhance therapeutic effects with recently updated ECT practices under the belief that the most appropriate treatments should be provided to the patients in need.
Bipolar Disorder ; Depression ; Drug Therapy ; Electroconvulsive Therapy* ; Evidence-Based Medicine ; Humans ; Mental Disorders ; Schizophrenia